Abstract
In the past decade the importance of the vascular endothelium as a multi-functional regulator of vascular smooth muscle physiology and pathophysiology has been appreciated. Indeed, the endothelium responds to hemodynamic stimuli (pressure, shear stress and wall strain) and locally manufactured mediators (such as bradykinin, prostaglandins and angiotensin) and in turn can release factors that can influence the adhesion and aggregation of circulating cells to the endothelium and the tone of vascular smooth muscle. In many diseases, including cirrhosis, atherosclerosis or diabetes, endothelial dysfunction manifested as an impairment of nitric oxide (NO) production may be an early hallmark of disease and a treatable entity. In this chapter the importance of NO as a mediator of vascular function and potential mechanisms leading to endothelial dysfunction will be discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Furchgott RF, Zawadski JV. The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1981;288:373-6.
Huang PL, Huang Z, Mashimo H et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase [See comments]. Nature 1995;377:239–42.
Shesely EG, Maeda N, Kim HS et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1996;93:13176–81.
Kuchan MJ, Frangos JA. Role of calcium and calmodulin in flow-induced nitric oxide production in endothelial cells. Am J Physiol. 1994;266:C628–36.
Fleming I, Bauersachs J, Fisslthaler B, Busse R. Ca2+-independent activation of the endothelial nitric oxide synthase in response to tyrosine phosphatase inhibitors and fluid shear stress. Circ Res. 1998;82:686–95.
Fulton D, Gratton JP, Sessa We. Post-translational control of endothelial nitric oxide synthase: why isn’t calcium/calmodulin enough? J Pharmacol Exp Ther. 2001;299:818–24.
Smart EJ, Graf GA, McNiven MA et al. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell BioI. 1999;19:7289–304.
Feron O, Belhassen L, Kobzik L, Smith TW, Kelly RA, Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Bioi Chern. 1996;271:22810–14.
Garcìa-Cardeñla G, Fan R, Stern DF, Liu J, Sessa We. Endothelial nitric oxide is regulated by tyrosine phosphorylation and interacts with caveolin-1. J Biol Chem. 1996;271:27237–40.
Ju H, Zou R, Venema VI, Venema Re. Direct interaction of endothelial nitric-oxide synthase and caveolin-l inhibits synthase activity. J Biol Chem. 1997;272:18522–5.
Feron O, Dessy C, Opel OJ, Arstall MA, Kelly RA, Michel T. Modulation of the endothelial nitric-oxide synthase-caveolin interaction in cardiac myocytes. Implications for the autonomic regulation of heart rate. J Biol Chem. 1998;273:30249–54.
Bucci M, Gratton JP, Rudie RD et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med. 2000;6:1362–7.
Gratton JP, Lin MI, Yu J et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell. 2003;4:31–9.
Razani B, Engelman JA, Wang XB et al. 2001. Caveolin-l null mice are viable but show evidence of hyper proliferative and vascular abnormalities. J Biol Chem. 2001; 276:38121–38.
Drab M, Verkade P, Elger M et al. 2001. Loss of caveolac, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001 293:2449–52.
Razani B, Woodman SE, Lisanti MP et al. Caveolae: from cell biology to animal physiology. Pharmacol Rev. 2002;54:431–67.
Shah V, Toruner M, Haddad F et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology. 1999; 117:1222–8.
Shah V, Cao S, Hendrickson H, Yao J, Katusic ZS et al. Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats. Am J Physiol Gastrointest Liver Physiol. 2001;280:G 1209–16.
Yokomori H, Oda M, Ogi M, Sakai K, Ishii H. Enhanced expression of endothelial nitric oxide synthase and caveolin-l in human cirrhosis. Liver. 2002;22:150–8.
Yokomori H, Oda M, Yoshimura K et al. Elevated expression of caveolin-1 at protein and mRNA level in human cirrhotic liver: relation with nitric oxide. J Gastroenterol. 2003;38:854–60.
Garcia-Cardena G, Fan R, Shah V et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature. 1998;392:821–4.
Ou J, Fontana JT, Ou Z et al. Heat shock protein 90 and tyrosine kinase regulate eNOS NO* generation but not NO* bioactivity. Am J Physiol Heart Circ Physiol. 2004; 286:H561–9.
Shah V, Wiest R, Garcia-Cardena G, Cadelina G, Groszmann RJ, Sessa We. Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am J Physiol. 1999;277:G463–8.
Bucci M, Roviezzo F, Cicala C, Sessa WC, Cirino G. Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo. Br J Pharmacol. 2000; 131:13–16.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media Dordrecht
About this paper
Cite this paper
Sessa, W.C. (2004). Endothelial-derived nitric oxide as a marker for healthy endothelium. In: Groszmann, R.J., Bosch, J. (eds) Portal Hypertension in the 21st Century. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-1042-9_3
Download citation
DOI: https://doi.org/10.1007/978-94-007-1042-9_3
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-3774-7
Online ISBN: 978-94-007-1042-9
eBook Packages: Springer Book Archive